Windtree Therapeutics $WINT Announces Positive Phase 2b Results In Early Cardiogenic Shock Treatment

  • 15 hours ago
Windtree Therapeutics has announced the results from the Phase 2b study of its lead drug candidate, istaroxime, in the treatment of cardiogenic shock due to heart failure. The data from the study will be instrumental in determining the optimal dosing regimen for a potential Phase 3 program.

Category

🗞
News

Recommended